

IMI2 - Call 15 webinar: Emerging translational safety technologies and tools for interrogating human immuno-biology



First Name	Last Name	Email	Country	Organization	Briefly, what would you bring to the project in terms of expertise, resources, activities?
Amélie	Abrantes	amelie.abrantes@u-bordeaux.fr	France	Université de Bordeaux	
ITZIAR	ACHA	iacha@bioef.org	Spain	Fundación Vasca de Innovación e Investigación Sanitarias - BIOEF	
Stefano	Benvenuti	sbenvenuti@telethon.it	Italy	Fondazione Telethon	
Daniela	Buser	daniela.buser@fhnw.ch	Switzerland	FHNW	Startup Experience and Network in Blockchain, Biology Studies, Master in Psychology, Working in Security
Célia	Cabral	celia.cabral@fmed.uc.pt	Portugal	Faculdade de Medicina, Universidade de Coimbra	
Mohamed Farouk	Chughlay	chughlayf@mmv.org	Switzerland	Medicines for Malaria Venture	Early phase antimalarial drug development experience including human volunteer infection studies.
Janete	Chung	janete.chung@uis.no	Norway	Stavanger Hospital University	
Jose Carlos	Diez-Masa	diez-masa@iqog.csic.es	Spain	Consejo Superior de Investigaciones Científicas	Platforms of HPLC and Capillary Electrophoresis for immunoglobulins characterization.
Christina	do Paço	dopacoc@mmv.org	Switzerland	Medicines for Malaria Venture (MMV)	
Astrid	Flandorfer	astrid.flandorfer@ffg.at	Austria	FFG	
Mireia	Gimenez	mgimenez@leitat.org	Spain	LEITAT	Extensive preclinical models; in depth mechanism of action investigation; biodistribution; organoid technology; Biosensors; NPs.
Núria	Ginés	ngines@leitat.org	Spain	Leitat	In-vitro cell assays, intestine and blood-brain barrier models, safety and toxicity studies, biochemical and cellular biomarkers
Jonathan	Gomez-Raja	jonathan.gomez@fundesalud.es	Spain	FundeSalud, Government of Extremadura	Hospitals (14), patients and expertise in infectious diseases and EU projects
Bas	Kremer	bas.kremer@tno.nl	Netherlands	TNO	Data science, analytics, immune health data tooling, network in immunology
Maryse	Letiembre	maryse.letiembre@irb.usi.ch	Switzerland	Institute for Research in Biomedicine (CH-Bellinzona)	IRB is a center of excellence in human immunology with state of the art molecular and immune technologies, and bioinformatic core
Wai Li	Ling	wai-li.ling@ibs.fr	France	Institut de Biologie Structurale	innate immunology, ISBG (Integrated Structural Biology Grenoble) platforms, characterizing nanoparticle-protein interaction
Concepción	Marañón	concepcion.maranon@genyo.es	Spain	GENYO Centre	Biomarker discovery in body fluids; immunomonitoring; autoimmune diseases and chronic infections; experience in IMI projects
Ezequiel	Mas del Molino	ezequiel.masdelmolino@bsc.es	Spain	Barcelona Supercomputing Center	Supercomputing and Biomedical expertise
Bechara	MFARREJ	mfarrejb@ipc.unicancer.fr	France	Institut Paoli Calmettes	Cellular Immunotherapy expertise, activation immunotherapies
Torben	Moos	moos@os.dk	Denmark	Aalborg University	Antibody technology. Preclinical (animal) models. In vitro cellular models of relevance for antibody permeability screening

Lorna	Morris	morris@lifeglimmer.com	Germany	Lifeglimmer GmbH	Clinical data and knowledge management, bioinformatics and statistics
Dean	Naisbitt	dnes@liv.ac.uk	United Kingdom	The University of Liverpool	Safety Immunopharmacology/toxicology
Christa	Noehammer	christa.noehammer@ait.ac.at	Austria	AIT Austrian Institute of Technology	mRNA-, small RNA-, protein- and immunoglobulin profiling using multiplexable high throughput technologies (microarrays, NGS etc)
Aida	Paniccia	apaniccia@telethon.it	Italy	Fondazione Telethon	
Ameeta	Parekh	ameeta.parekh@fda.hhs.gov	United States	FDA CDER	
Anett	Pfeiffer	a.pfeiffer@eurice.eu	Germany	EURICE GmbH	Expertise in collaborative project management and exploitation management (management partner in running IMI projects)
Sabine	Possmann	possmann@arttic.eu	Germany	ARTTIC	ARTTIC - 30 years of experience in project management of EU-funded projects and dissemination expert
Vaclovas	Radvilas	vaclovas.radvilas@zeclinics.com	Spain	ZeClinics SL	Generation of disease models (using zebrafish) to address the efficacy and safety of novel drugs impacting the immune system
Doris	Rakoczy	doris.rakoczy@ait.ac.at	Austria	AIT Austrian Institute of Technology GmbH	
Viviana	Roman	rviviana30@yahoo.com	Romania	Institute of Virology- Center of Immunology	
Maria Grazia	Santagati	mariagrazia.santagati@tin.it	Italy	self employed	
Ashwini	Sathnur	ashwiniashis@yahoo.com	India	United Nations Development Programme	Inclusive Development
Mary	Wang	mwang@telethon.it	Italy	Fondazione Telethon	Network of 25 high quality biobanks (EuroBioBank) located in 11 countries, expertise in rare diseases, sample management